firstwordpharmaJuly 02, 2021
Tag: Caribou Biosciences , IPO , chRDNA
Caribou Biosciences has filed for an initial public offering of $100 million, reported StreetInsider.
The company is working on applying its hybrid RNA-DNA CRISPR platform (chRDNA) toward the development of next-generation, genome-edited cell therapies.
Caribou says its chRDNA technology has demonstrated superior specificity and high efficiency in preclinical studies, enabling multiple, precise genomic edits, while maintaining genomic integrity.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: